Recent news on Hydralazine Hydrochloride

NitroMed Announces Sale of Common Stock  -  May 24, 2007
Business Wire (press release),NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil ® (isosorbide dinitrate/hydralazine hydrochloride),

NitroMed To Report Financial Results for First Fiscal Quarter 2007  -  Apr 25, 2007
PharmaLive.com (press release),NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride),

Study: Identical Doses of BiDil Components Are Not Bioequivalent ...  -  27 Mar 2007
PharmaLive.com (press release),Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness and tingling, which may be related to an

NitroMed Reports Financial Results for Fourth Quarter and Full ...  -  Mar 8, 2007
Genetic Engineering News (press release),BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) revenues for the fourth quarter were also $3.5 million, an increase of $0.2 million over the

Michael L. Sabolinski, MD Resigns from NitroMed  -  Mar 7, 2007
PharmaLive.com (press release),NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride),

NitroMed (NTMD) Announces License Agreement with Elan Pharma (ELN)  -  Feb 12, 2007
StreetInsider.com (subscription),...as its sole active combination of ingredients, the combination of the active drug substances isosorbide dinitrate and hydralazine hydrochloride.

BiDil for Heart Failure in Black Patients: The US Food and Drug ...  -  Jan 2, 2007
Annals of Internal MedicineCritics of the US Food and Drug Administration (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate,

CORRECTING and REPLACING NitroMed to Present at JPMorgan ...  -  Jan 4, 2007
Genetic Engineering News (press release),NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride),

BiDil for Heart Failure in Black Patients: Implications of the US ...  -  Jan 2, 2007
Annals of Internal MedicineIn 2005, the combination of hydralazine hydrochloride and isosorbide dinitrate was approved by the US Food and Drug Administration (FDA) for treating heart

NitroMed (NTMD) Reports a Q3 Loss of $0.45  Nov 2, 2006
NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally ... -StreetInsider.com (subscription), NitroMed Reports Financial Results for Third Quarter 2006  Nov 2, 2006
Net sales of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) accounted for all of the Company's revenue during the first nine months of 2006, and ... -Genetic Engineering News (press release), NitroMed Third Quarter 2006 Earnings Call and Webcast To Be Held ...  Oct 26, 2006
...of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil ® (isosorbide dinitrate/hydralazine hydrochloride), an orally ... -Business Wire (press release), NitroMed Revises Sales and Marketing Strategy - Accelerates ...  Oct 11, 2006
...to focus its resources on the accelerated development of an extended release formulation of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), known as ... -Genetic Engineering News (press release), Hydralazine Hydrochloride Recall Update  Aug 29, 2006
Luitpold Pharmaceuticals has issued an updated voluntary recall to health care professionals for hydralazine hydrochloride 20 mg/mL, 1 mL single-dose injection ... -Facts and Comparisons

New BiDil Data Highlighted at Annual Heart Failure Society of ...  Sep 11, 2006
NTMD) announced today that five poster presentations highlighting new findings related to BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) will be ... -Genetic Engineering News

NitroMed to Present at UBS Global Life Sciences Conference ...  Sep 19, 2006
...of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... -Business Wire

Hydralazine Hydrochloride Injection Recall  Aug 8, 2006
Luitpold Pharmaceuticals has issued a voluntary recall to health care professionals for hydralazine hydrochloride 20 mg/mL, 1 mL single-dose injection vials ... -Facts and Comparisons

NitroMed Reports Financial Results for Second Quarter 2006 ...  Aug 3, 2006
Product sales of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) accounted for all of the Company's revenue during the first half of 2006. ... -Business Wire

FDA MedWatch - Hydralazine HCl Injection, USP 20 mg/mL (Luitpold ...  Aug 4, 2006
...cease. You are hereby instructed to isolate your inventory of the above lot number of Hydralazine Hydrochloride Injection, USP. ... -PharmaLive.com

NitroMed Second Quarter 2006 Earnings Call and Webcast to Be Held ...  Jul 27, 2006
...of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... -PharmaLive.com



FDA Confirms No Drugs are Therapeutically Equivalent to BiDil(R)  May 4, 2006
...drug that is therapeutically equivalent or substitutable to BiDil, the fixed-dose combination of isosorbide dinitrate/hydralazine hydrochloride, approved as ... - Genetic Engineering News

NitroMed Reports Financial Results for First Quarter 2006 ...  May 2, 2006
Product sales of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) accounted for all of the Company's revenue during the first quarter of 2006, and ... - Genetic Engineering News

NitroMed Says FDA Confirms No Drug Therapeutically Equivalent Or ...  May 4, 2006
Moreover, the FDA confirmed that neither approved labeling for isosorbide dinitrate nor approved labeling for hydralazine hydrochloride contains information ... - Trading Markets

NitroMed to Present at Morgan Stanley's Global Healthcare ...  Apr 27, 2006
...the Company's progress and plans, particularly with respect to the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), in this open ... - Genetic Engineering News

NitroMed First Quarter 2006 Earnings Call and Webcast Scheduled ...  Apr 24, 2006
...of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... - PharmaLive.com





NitroMed Restructures R&D Operations; Extended Release BiDil(R) ...  Mar 30, 2006
Company will focus on the continued development of both an extended release formulation of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), as well ... - Genetic Engineering News

Researchers Identify Gene Variations That May Determine Which ...  Mar 13, 2006
American Heart Failure Trial (A-HeFT), the clinical trial supporting effectiveness of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), that may ... - International News Service

African American Heart Failure Trial Shows Women and Men Both ...  Mar 14, 2006
...demonstrated similar positive clinical outcomes for both black men and black women taking BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) in addition ... - Genetic Engineering News

Clinical Response to BiDil(R) Evaluated by Baseline Blood Pressure ...  Mar 13, 2006
...(NASDAQ:NTMD) announced data from a continuing analysis of patients treated with BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) in the African ... - Genetic Engineering News

When Discrimination Saves Lives  Mar 29, 2006
...of Lexington, Massachusetts, combines isosorbide dinitrate and hydralazine hydrochloride, which cause arteries and veins to dilate and allow blood to flow ... - Pennsylvania Independent

NitroMed Cuts Back R&D To Ready For BiDil Sales Push  Apr 3, 2006
BiDil consists of a combination of two generic drugs, isosorbide dinitrate and hydralazine hydrochloride, taken three times per day. ... - BioWorld Online (subscription)

NitroMed Board Appoints New Senior Management  Mar 21, 2006
Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... - Genetic Engineering News

BiDil Benefits All Black Heart Failure Patients: Study  Mar 14, 2006
Failure Trial (A-HeFT) showed that both women (228) and men (290) treated with BiDil (isosorbide dinitrate/hydralazine hydrochloride) experienced improved ... - KPHO Phoenix



NitroMed to Present at the SG Cowen & Co. Health Care Conference ...  Feb 28, 2006
Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) on Monday ... - Genetic Engineering News,

NitroMed to Host Fourth Quarter and Year End 2005 Earnings Call ...  Feb 22, 2006
Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... - Genetic Engineering News,

NitroMed to Present at BIO CEO & Investor Conference; February 14 ...  Feb 7, 2006
Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) on Tuesday ... - Genetic Engineering News

NitroMed Announces Sale of Common Stock  Jan 25, 2006
...corporate purposes, including the continued commercial launch of NitroMed's first marketed product, BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride). ... - Genetic Engineering News

NitroMed Sells Stock  Jan 25, 2006
...corporate purposes, including the continued commercial launch of NitroMed's first marketed product, BiDil (isosorbide dinitrate/hydralazine hydrochloride). - TheStreet.com

NitroMed $62.5M Placement Supporting Growth Of BiDil  Jan 25, 2006
...company intends to use the proceeds for general corporate purposes, including commercializing BiDil (isosorbide dinitrate/hydralazine hydrochloride), which was ... - BioWorld Online (subscription)

Gerald W. Bruce Joins NitroMed as Vice President, Sales  Jan 17, 2006
Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride), an orally ... - Genetic Engineering News

NitroMed Announces Optimization of BiDil(R) Contract Sales Force  Jan 20, 2006
Publicis Selling Solutions has been modified to now staff 144 of the original 195 BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) sales territories. ... - Genetic Engineering News

NitroMed Promotes Michael Sabolinski, MD to the Position of Chief ...  Jan 7, 2006
...and participate in certain key decision making processes relative to the development of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) outside of ... - New Age Media Concepts

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional